Category: Latest News

DiscoveryBioMed, Inc. is developing a novel and unprecedented “dual action” small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases

DiscoveryBioMed, Inc. (DBM, Inc.), fueled by recent advances in its Respiratory Diseases R&D program, has discovered and is developing a novel class of small molecule monotherapy that affects both major drug targets in CF. Proper function of the two target proteins that serve as channels for ions (conduits or transporters) for salt and water across the ciliated membrane that lines the airways, the cystic fibrosis transmembrane conductance regulator or CFTR (the protein product of the CF gene, a chloride ion channel) and ENaC (the epithelial sodium ion channel), becomes very abnormal in this devastating disease of children and young adults.

Continue Reading »

DiscoveryBioMed, Inc. is awarded a new Phase 2 SBIR grant award to develop new medicines to fight the diabetes and obesity epidemic in the US and globally

DiscoveryBioMed, Inc. (DBM, Inc.) has learned in recent days that it has been awarded a $1.61M Phase 2 Small Business Innovation Research (SBIR) grant award from the National Institutes of Health and its National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) to develop novel ‘first in class’ small molecule drugs to fight multiple disease abnormalities caused by high blood sugar (hyperglycemia) and high blood fat such as metabolic syndrome, type 2 diabetes mellitus and obesity.

Continue Reading »